Jazz Pharmaceuticals (JAZZ) Q2 FY26 earnings call

Jazz Pharmaceuticals delivered a strong second quarter, driven by robust performance across its diversified portfolio, particularly in rare sleep and oncology. The company raised its full-year revenue guidance, reflecting confidence in sustained demand and strategic investments. Key pipeline advancements, including the anticipated zanidatamab approval, position Jazz for continued growth and value creation, while the company actively manages portfolio evolution and invests in future innovation.